Revising the 'National List of Essential Medicines' (NLEM), the central govenrment has slashed the prices of 39 commonly used drugs.
The prices were slashed for the anti-cancer, anti-diabetes, antiviral, antibacterial, antiretroviral, anti-TB drugs, and also for some that are used in Covid treatment.
The experts working on the NLEM list have deleted 16 odd drugs from the list.
The Indian Council of Medical Research (ICMR) has been working for a long time to extend price control on medicines.
The commonly used drugs, which were brought under the price cap includes Teneligliptin -- an anti diabetes drug, popular anti-TB drugs, Ivermectin -- used in Covid treatment, Rotavirus vaccine, among others.
The government had begun an exercise for the revision of the NLEM, which was notified in 2015 and implemented in 2016.
It is a departure from the present practice, where all essential medicines automatically go under price control.
The Standing National Committee on Medicines was tasked with preparing the list of which medicines should be available in adequate numbers and assured quantity.
The committee headed by Balram Bhargava, Secretary in the Department of Health Research and Director General of the ICMR, send the list to a second committee comprising senior officials from NITI Aayog, Health Secretary and Secretary in the Department of Pharmaceuticals, which decides on which drugs are to be put under the price cap.
--IANS
avr/shs/in
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)